-A A +A
B-cell lymphoma is associated with incomplete response to treatment, and the development of effective strategies targeting this disease remains challenging. A new personalized B-cell lymphoma therapy, based on a site-specific receptor-mediated drug delivery system, was developed in this study. Specifically, natural silica-based nanoparticles (diatomite) were modified to actively target the antiapoptotic factor B-cell lymphoma/leukemia 2 (Bcl2) with small interfering RNA (siRNA). An idiotype-specific peptide (Id-peptide) specifically recognized by the hypervariable region of surface immunoglobulin B-cell receptor was exploited as a homing device to ensure specific targeting of lymphoma cells. Specific nanoparticle uptake, driven by the Id-peptide, was evaluated by flow cytometry and confocal microscopy and was increased by approximately threefold in target cells compared with nonspecific myeloma cells and …
Dove Press
Publication date: 
1 Jan 2016

Nicola M Martucci, Nunzia Migliaccio, Immacolata Ruggiero, Francesco Albano, Gaetano Calì, Simona Romano, Monica Terracciano, Ilaria Rea, Paolo Arcari, Annalisa Lamberti

Biblio References: 
Volume: 11 Pages: 6089
International journal of nanomedicine